Results 211 to 220 of about 35,533 (292)

Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years

open access: yesBJU International, EarlyView.
Objective To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised
Mario Bitar   +7 more
wiley   +1 more source

The cost‐effectiveness of intraoperative margin assessment strategies during radical prostatectomy

open access: yesBJU International, EarlyView.
Objective To determine whether current intraoperative margin assessment (IOMA) techniques (such as Neurovascular Structure Adjacent Frozen‐section Examination [NeuroSAFE] or confocal laser microscopy [CLM]) used during radical prostatectomy (RP) to enhance nerve‐sparing surgery (NSS) while reducing positive surgical margins (PSMs) justify their extra ...
Joost van Drumpt   +7 more
wiley   +1 more source

The Associations Between Serum Sex Hormones, Erectile Function, and Sex Drive: The Olmsted County Study of Urinary Symptoms and Health Status Among Men

open access: green, 2008
Naomi M. Gades   +8 more
openalex   +1 more source

Cave Palaeolithic of the Ural Mountains – a review

open access: yesBoreas, EarlyView.
The Ural Mountains are of fundamental importance for studying early human migrations along the geographical limits between Europe and Asia. Geological processes and past climates gave rise to numerous caves, mostly in Palaeozoic carbonate formations.
Jiri Chlachula
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy